Europe Companion Diagnostics Market (2019-2025)
The Europe Companion Diagnostics Market would witness market growth of 18.1% CAGR during the forecast period (2019-2025).
Companion diagnostics is an in vitro medical device which offers essential information for safe and effective use of a biological output or a corresponding drug. The test also helps healthcare professionals to decide if a certain therapy product is beneficial to patients and can tackle any possible severe side effects. The development of the companion diagnostics industry will be stepping up with increasing cases of adverse drug reaction (ADR). Due to the incompatibility of certain patients with conventional treatment, adverse drug reactions occur and may cause life-threatening results. However, elevated costs of companion diagnostics can to some extent hinder business growth.
Increased R&D of focused therapies, increasing demand for the personalized medication in developing markets, and the identification of new biomarkers under multiple circumstances in addition to a larger amount of unmet cancer therapy requirements, are altogether pushing the market towards exponential growth during the forecast period.
Based on Technology, the market is segmented into Immunohistochemistry, Polymerase chain reaction (PCR), Next generation sequencing (NGS), In Situ Hybridization, and Other Technology. Based on Indication, the market is segmented into Oncology, Neurology and Other Indications. Further based on Cancer Type, the Oncology market is segmented into Breast Cancer, Colorectal Cancer, Lung Cancer, Blood Cancer and Other Cancer Type. Based on countries, the market is segmented into Germany, UK, France, Russia, Spain, Italy, and Rest of Europe.
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Agilent Technologies, Inc., Almac Group, ARUP Laboratories, Inc., Abbott Laboratories (Abbott Laboratories Molecular, Inc.), Danaher Corporation, Thermo Fisher Scientific, Inc., Hologic, Inc., Novartis AG, Illumina, Inc., Qiagen N.V.
Scope of the Study
Market Segmentation:
By Technology
Companion diagnostics is an in vitro medical device which offers essential information for safe and effective use of a biological output or a corresponding drug. The test also helps healthcare professionals to decide if a certain therapy product is beneficial to patients and can tackle any possible severe side effects. The development of the companion diagnostics industry will be stepping up with increasing cases of adverse drug reaction (ADR). Due to the incompatibility of certain patients with conventional treatment, adverse drug reactions occur and may cause life-threatening results. However, elevated costs of companion diagnostics can to some extent hinder business growth.
Increased R&D of focused therapies, increasing demand for the personalized medication in developing markets, and the identification of new biomarkers under multiple circumstances in addition to a larger amount of unmet cancer therapy requirements, are altogether pushing the market towards exponential growth during the forecast period.
Based on Technology, the market is segmented into Immunohistochemistry, Polymerase chain reaction (PCR), Next generation sequencing (NGS), In Situ Hybridization, and Other Technology. Based on Indication, the market is segmented into Oncology, Neurology and Other Indications. Further based on Cancer Type, the Oncology market is segmented into Breast Cancer, Colorectal Cancer, Lung Cancer, Blood Cancer and Other Cancer Type. Based on countries, the market is segmented into Germany, UK, France, Russia, Spain, Italy, and Rest of Europe.
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Agilent Technologies, Inc., Almac Group, ARUP Laboratories, Inc., Abbott Laboratories (Abbott Laboratories Molecular, Inc.), Danaher Corporation, Thermo Fisher Scientific, Inc., Hologic, Inc., Novartis AG, Illumina, Inc., Qiagen N.V.
Scope of the Study
Market Segmentation:
By Technology
- Immunohistochemistry
- Polymerase chain reaction (PCR)
- Next generation sequencing (NGS)
- In Situ Hybridization and
- Other Technology
- Oncology
- Neurology and
- Other Indications
- Breast Cancer
- Colorectal Cancer
- Lung Cancer
- Blood Cancer and
- Other Cancer Type
- Germany
- UK
- France
- Russia
- Spain
- Italy
- Rest of Europe
- Agilent Technologies, Inc.
- Almac Group
- ARUP Laboratories, Inc.
- Abbott Laboratories (Abbott Laboratories Molecular, Inc.)
- Danaher Corporation
- Thermo Fisher Scientific, Inc.
- Hologic, Inc.
- Novartis AG
- Illumina, Inc.
- Qiagen N.V.
- Exhaustive coverage
- Highest number of market tables and figures
- Subscription based model available
- Guaranteed best price
- Assured post sales research support with 10% customization free
CHAPTER 1. MARKET SCOPE & METHODOLOGY
1.1 Market Definition
1.2 Objectives
1.3 Market Scope
1.4 Segmentation
1.4.1 Europe Companion Diagnostics Market, by Technology
1.4.2 Europe Companion Diagnostics Market, by Indication
1.4.3 Europe Companion Diagnostics Market, by Cancer Type
1.4.4 Europe Companion Diagnostics Market, by Country
1.5 Methodology for the research
CHAPTER 2. MARKET OVERVIEW
2.1 Introduction
2.1.1 Overview
2.1.2 Executive Summary
2.1.3 Market Composition and Scenario
2.2 Key Factors Impacting the Market
2.2.1 Market Drivers
2.2.2 Market Restraints
CHAPTER 3. EUROPE COMPANION DIAGNOSTICS MARKET BY TECHNOLOGY
3.1 Europe Immunohistochemistry Market by Country
3.2 Europe Polymerase chain reaction (PCR) Market by Country
3.3 Europe Next generation sequencing (NGS) Market by Country
3.4 Europe In Situ Hybridization Market by Country
3.5 Europe Other Technology Market by Country
CHAPTER 4. EUROPE COMPANION DIAGNOSTICS MARKET BY INDICATION
4.1 Europe Oncology Companion Diagnostics Market by Country
4.2 Europe Companion Diagnostics Market by Cancer Type
4.2.1 Europe Breast Cancer Companion Diagnostics by Country
4.2.2 Europe Colorectal Cancer Companion Diagnostics by Country
4.2.3 Europe Lung Cancer Companion Diagnostics by Country
4.2.4 Europe Blood Cancer Companion Diagnostics by Country
4.2.5 Europe Other Cancer Type Companion Diagnostics Market by Country
4.3 Europe Neurology Companion Diagnostics Market by Country
4.4 Europe Other Indications Companion Diagnostics Market by Country
CHAPTER 5. EUROPE COMPANION DIAGNOSTICS MARKET BY COUNTRY
5.1 Germany Companion Diagnostics Market
5.1.1 Germany Companion Diagnostics Market by Technology
5.1.2 Germany Companion Diagnostics Market by Indication
5.1.2.1 Germany Companion Diagnostics Market by Cancer Type
5.2 UK Companion Diagnostics Market
5.2.1 UK Companion Diagnostics Market by Technology
5.2.2 UK Companion Diagnostics Market by Indication
5.2.2.1 UK Companion Diagnostics Market by Cancer Type
5.3 France Companion Diagnostics Market
5.3.1 France Companion Diagnostics Market by Technology
5.3.2 France Companion Diagnostics Market by Indication
5.3.2.1 France Companion Diagnostics Market by Cancer Type
5.4 Russia Companion Diagnostics Market
5.4.1 Russia Companion Diagnostics Market by Technology
5.4.2 Russia Companion Diagnostics Market by Indication
5.4.2.1 Russia Companion Diagnostics Market by Cancer Type
5.5 Spain Companion Diagnostics Market
5.5.1 Spain Companion Diagnostics Market by Technology
5.5.2 Spain Companion Diagnostics Market by Indication
5.5.2.1 Spain Companion Diagnostics Market by Cancer Type
5.6 Italy Companion Diagnostics Market
5.6.1 Italy Companion Diagnostics Market by Technology
5.6.2 Italy Companion Diagnostics Market by Indication
5.6.2.1 Italy Companion Diagnostics Market by Cancer Type
5.7 Rest of Europe Companion Diagnostics Market
5.7.1 Rest of Europe Companion Diagnostics Market by Technology
5.7.2 Rest of Europe Companion Diagnostics Market by Indication
5.7.2.1 Rest of Europe Companion Diagnostics Market by Cancer Type
CHAPTER 6. COMPANY PROFILES
6.1 Agilent Technologies, Inc.
6.1.1 Company Overview
6.1.2 Financial Analysis
6.1.3 Segmental and Regional Analysis
6.1.4 Research & Development Expense
6.1.5 Recent strategies and developments:
6.1.5.1 Product launches:
6.1.5.2 Expansions:
6.2 Almac Group
6.2.1 Company Overview
6.2.1 Recent strategies and developments:
6.2.1.1 Collaborations, partnerships and agreements:
6.3 ARUP Laboratories, Inc.
6.3.1 Company Overview
6.4 Abbott Laboratories (Abbott Laboratories Molecular, Inc.)
6.4.1 Company Overview
6.4.2 Financial Analysis
6.4.3 Segmental and Regional Analysis
6.4.4 Research & Development Expense
6.5 Danaher Corporation
6.5.1 Company Overview
6.5.2 Financial Analysis
6.5.3 Segmental and Regional Analysis
6.5.4 Research & Development Expense
6.5.5 Recent strategies and developments:
6.5.5.1 Acquisition and mergers:
6.6 Thermo Fischer Scientific, Inc.
6.6.1 Company Overview
6.6.2 Financial Analysis
6.6.3 Segmental and Regional Analysis
6.6.4 Research & Development Expense
6.6.5 Recent strategies and developments:
6.6.5.1 Collaborations, partnerships and agreements:
6.6.5.2 Expansions:
6.7 Hologic, Inc.
6.7.1 Company Overview
6.7.2 Financial Analysis
6.7.3 Segmental and Regional Analysis
6.7.4 Research & Development Expense
6.7.5 Recent strategies and developments:
6.7.5.1 Product launches:
6.7.5.2 Acquisition and mergers:
6.8 Novartis AG
6.8.1 Company Overview
6.8.2 Financial Analysis
6.8.3 Segmental and Regional Analysis
6.8.4 Research & Development Expense
6.8.5 Recent strategies and developments:
6.8.5.1 Collaborations, partnerships and agreements:
6.9 Illumina, Inc.
6.9.1 Company Overview
6.9.2 Financial Analysis
6.9.3 Regional Analysis
6.9.4 Research & Development Expense
6.9.5 Recent strategies and developments:
6.9.5.1 Product launches:
6.9.5.2 Acquisition and mergers:
6.9.5.3 Collaborations, partnerships and agreements:
6.1 Qiagen N.V.
6.10.1 Company Overview
6.10.2 Financial Analysis
6.10.3 Regional Analysis
6.10.4 Research & Development Expense
6.10.5 Recent strategies and developments:
6.10.5.1 Product launches:
6.10.5.2 Collaborations, partnerships and agreements:
1.1 Market Definition
1.2 Objectives
1.3 Market Scope
1.4 Segmentation
1.4.1 Europe Companion Diagnostics Market, by Technology
1.4.2 Europe Companion Diagnostics Market, by Indication
1.4.3 Europe Companion Diagnostics Market, by Cancer Type
1.4.4 Europe Companion Diagnostics Market, by Country
1.5 Methodology for the research
CHAPTER 2. MARKET OVERVIEW
2.1 Introduction
2.1.1 Overview
2.1.2 Executive Summary
2.1.3 Market Composition and Scenario
2.2 Key Factors Impacting the Market
2.2.1 Market Drivers
2.2.2 Market Restraints
CHAPTER 3. EUROPE COMPANION DIAGNOSTICS MARKET BY TECHNOLOGY
3.1 Europe Immunohistochemistry Market by Country
3.2 Europe Polymerase chain reaction (PCR) Market by Country
3.3 Europe Next generation sequencing (NGS) Market by Country
3.4 Europe In Situ Hybridization Market by Country
3.5 Europe Other Technology Market by Country
CHAPTER 4. EUROPE COMPANION DIAGNOSTICS MARKET BY INDICATION
4.1 Europe Oncology Companion Diagnostics Market by Country
4.2 Europe Companion Diagnostics Market by Cancer Type
4.2.1 Europe Breast Cancer Companion Diagnostics by Country
4.2.2 Europe Colorectal Cancer Companion Diagnostics by Country
4.2.3 Europe Lung Cancer Companion Diagnostics by Country
4.2.4 Europe Blood Cancer Companion Diagnostics by Country
4.2.5 Europe Other Cancer Type Companion Diagnostics Market by Country
4.3 Europe Neurology Companion Diagnostics Market by Country
4.4 Europe Other Indications Companion Diagnostics Market by Country
CHAPTER 5. EUROPE COMPANION DIAGNOSTICS MARKET BY COUNTRY
5.1 Germany Companion Diagnostics Market
5.1.1 Germany Companion Diagnostics Market by Technology
5.1.2 Germany Companion Diagnostics Market by Indication
5.1.2.1 Germany Companion Diagnostics Market by Cancer Type
5.2 UK Companion Diagnostics Market
5.2.1 UK Companion Diagnostics Market by Technology
5.2.2 UK Companion Diagnostics Market by Indication
5.2.2.1 UK Companion Diagnostics Market by Cancer Type
5.3 France Companion Diagnostics Market
5.3.1 France Companion Diagnostics Market by Technology
5.3.2 France Companion Diagnostics Market by Indication
5.3.2.1 France Companion Diagnostics Market by Cancer Type
5.4 Russia Companion Diagnostics Market
5.4.1 Russia Companion Diagnostics Market by Technology
5.4.2 Russia Companion Diagnostics Market by Indication
5.4.2.1 Russia Companion Diagnostics Market by Cancer Type
5.5 Spain Companion Diagnostics Market
5.5.1 Spain Companion Diagnostics Market by Technology
5.5.2 Spain Companion Diagnostics Market by Indication
5.5.2.1 Spain Companion Diagnostics Market by Cancer Type
5.6 Italy Companion Diagnostics Market
5.6.1 Italy Companion Diagnostics Market by Technology
5.6.2 Italy Companion Diagnostics Market by Indication
5.6.2.1 Italy Companion Diagnostics Market by Cancer Type
5.7 Rest of Europe Companion Diagnostics Market
5.7.1 Rest of Europe Companion Diagnostics Market by Technology
5.7.2 Rest of Europe Companion Diagnostics Market by Indication
5.7.2.1 Rest of Europe Companion Diagnostics Market by Cancer Type
CHAPTER 6. COMPANY PROFILES
6.1 Agilent Technologies, Inc.
6.1.1 Company Overview
6.1.2 Financial Analysis
6.1.3 Segmental and Regional Analysis
6.1.4 Research & Development Expense
6.1.5 Recent strategies and developments:
6.1.5.1 Product launches:
6.1.5.2 Expansions:
6.2 Almac Group
6.2.1 Company Overview
6.2.1 Recent strategies and developments:
6.2.1.1 Collaborations, partnerships and agreements:
6.3 ARUP Laboratories, Inc.
6.3.1 Company Overview
6.4 Abbott Laboratories (Abbott Laboratories Molecular, Inc.)
6.4.1 Company Overview
6.4.2 Financial Analysis
6.4.3 Segmental and Regional Analysis
6.4.4 Research & Development Expense
6.5 Danaher Corporation
6.5.1 Company Overview
6.5.2 Financial Analysis
6.5.3 Segmental and Regional Analysis
6.5.4 Research & Development Expense
6.5.5 Recent strategies and developments:
6.5.5.1 Acquisition and mergers:
6.6 Thermo Fischer Scientific, Inc.
6.6.1 Company Overview
6.6.2 Financial Analysis
6.6.3 Segmental and Regional Analysis
6.6.4 Research & Development Expense
6.6.5 Recent strategies and developments:
6.6.5.1 Collaborations, partnerships and agreements:
6.6.5.2 Expansions:
6.7 Hologic, Inc.
6.7.1 Company Overview
6.7.2 Financial Analysis
6.7.3 Segmental and Regional Analysis
6.7.4 Research & Development Expense
6.7.5 Recent strategies and developments:
6.7.5.1 Product launches:
6.7.5.2 Acquisition and mergers:
6.8 Novartis AG
6.8.1 Company Overview
6.8.2 Financial Analysis
6.8.3 Segmental and Regional Analysis
6.8.4 Research & Development Expense
6.8.5 Recent strategies and developments:
6.8.5.1 Collaborations, partnerships and agreements:
6.9 Illumina, Inc.
6.9.1 Company Overview
6.9.2 Financial Analysis
6.9.3 Regional Analysis
6.9.4 Research & Development Expense
6.9.5 Recent strategies and developments:
6.9.5.1 Product launches:
6.9.5.2 Acquisition and mergers:
6.9.5.3 Collaborations, partnerships and agreements:
6.1 Qiagen N.V.
6.10.1 Company Overview
6.10.2 Financial Analysis
6.10.3 Regional Analysis
6.10.4 Research & Development Expense
6.10.5 Recent strategies and developments:
6.10.5.1 Product launches:
6.10.5.2 Collaborations, partnerships and agreements:
LIST OF TABLES
TABLE 1 EUROPE COMPANION DIAGNOSTICS MARKET, 2015 - 2018, USD MILLION
TABLE 2 EUROPE COMPANION DIAGNOSTICS MARKET, 2019 - 2025, USD MILLION
TABLE 3 EUROPE COMPANION DIAGNOSTICS MARKET BY TECHNOLOGY, 2015 - 2018, USD MILLION
TABLE 4 EUROPE COMPANION DIAGNOSTICS MARKET BY TECHNOLOGY, 2019 - 2025, USD MILLION
TABLE 5 EUROPE IMMUNOHISTOCHEMISTRY MARKET BY COUNTRY, 2015 - 2018, USD MILLION
TABLE 6 EUROPE IMMUNOHISTOCHEMISTRY MARKET BY COUNTRY, 2019 - 2025, USD MILLION
TABLE 7 EUROPE POLYMERASE CHAIN REACTION (PCR) MARKET BY COUNTRY, 2015 - 2018, USD MILLION
TABLE 8 EUROPE POLYMERASE CHAIN REACTION (PCR) MARKET BY COUNTRY, 2019 - 2025, USD MILLION
TABLE 9 EUROPE NEXT GENERATION SEQUENCING (NGS) MARKET BY COUNTRY, 2015 - 2018, USD MILLION
TABLE 10 EUROPE NEXT GENERATION SEQUENCING (NGS) MARKET BY COUNTRY, 2019 - 2025, USD MILLION
TABLE 11 EUROPE IN SITU HYBRIDIZATION MARKET BY COUNTRY, 2015 - 2018, USD MILLION
TABLE 12 EUROPE IN SITU HYBRIDIZATION MARKET BY COUNTRY, 2019 - 2025, USD MILLION
TABLE 13 EUROPE OTHER TECHNOLOGY MARKET BY COUNTRY, 2015 - 2018, USD MILLION
TABLE 14 EUROPE OTHER TECHNOLOGY MARKET BY COUNTRY, 2019 - 2025, USD MILLION
TABLE 15 EUROPE COMPANION DIAGNOSTICS MARKET BY INDICATION, 2015 - 2018, USD MILLION
TABLE 16 EUROPE COMPANION DIAGNOSTICS MARKET BY INDICATION, 2019 - 2025, USD MILLION
TABLE 17 EUROPE ONCOLOGY COMPANION DIAGNOSTICS MARKET BY COUNTRY, 2015 - 2018, USD MILLION
TABLE 18 EUROPE ONCOLOGY COMPANION DIAGNOSTICS MARKET BY COUNTRY, 2019 - 2025, USD MILLION
TABLE 19 EUROPE COMPANION DIAGNOSTICS MARKET BY CANCER TYPE, 2015 - 2018, USD MILLION
TABLE 20 EUROPE COMPANION DIAGNOSTICS MARKET BY CANCER TYPE, 2019 - 2025, USD MILLION
TABLE 21 EUROPE BREAST CANCER COMPANION DIAGNOSTICS BY COUNTRY, 2015 - 2018, USD MILLION
TABLE 22 EUROPE BREAST CANCER COMPANION DIAGNOSTICS BY COUNTRY, 2019 - 2025, USD MILLION
TABLE 23 EUROPE COLORECTAL CANCER COMPANION DIAGNOSTICS BY COUNTRY, 2015 - 2018, USD MILLION
TABLE 24 EUROPE COLORECTAL CANCER COMPANION DIAGNOSTICS BY COUNTRY, 2019 - 2025, USD MILLION
TABLE 25 EUROPE LUNG CANCER COMPANION DIAGNOSTICS BY COUNTRY, 2015 - 2018, USD MILLION
TABLE 26 EUROPE LUNG CANCER COMPANION DIAGNOSTICS BY COUNTRY, 2019 - 2025, USD MILLION
TABLE 27 EUROPE BLOOD CANCER COMPANION DIAGNOSTICS BY COUNTRY, 2015 - 2018, USD MILLION
TABLE 28 EUROPE BLOOD CANCER COMPANION DIAGNOSTICS BY COUNTRY, 2019 - 2025, USD MILLION
TABLE 29 EUROPE OTHER CANCER TYPE COMPANION DIAGNOSTICS MARKET BY COUNTRY, 2015 - 2018, USD MILLION
TABLE 30 EUROPE OTHER CANCER TYPE COMPANION DIAGNOSTICS MARKET BY COUNTRY, 2019 - 2025, USD MILLION
TABLE 31 EUROPE NEUROLOGY COMPANION DIAGNOSTICS MARKET BY COUNTRY, 2015 - 2018, USD MILLION
TABLE 32 EUROPE NEUROLOGY COMPANION DIAGNOSTICS MARKET BY COUNTRY, 2019 - 2025, USD MILLION
TABLE 33 EUROPE OTHER INDICATIONS COMPANION DIAGNOSTICS MARKET BY COUNTRY, 2015 - 2018, USD MILLION
TABLE 34 EUROPE OTHER INDICATIONS COMPANION DIAGNOSTICS MARKET BY COUNTRY, 2019 - 2025, USD MILLION
TABLE 35 EUROPE COMPANION DIAGNOSTICS MARKET BY COUNTRY, 2015 - 2018, USD MILLION
TABLE 36 EUROPE COMPANION DIAGNOSTICS MARKET BY COUNTRY, 2019 - 2025, USD MILLION
TABLE 37 GERMANY COMPANION DIAGNOSTICS MARKET, 2015 - 2018, USD MILLION
TABLE 38 GERMANY COMPANION DIAGNOSTICS MARKET, 2019 - 2025, USD MILLION
TABLE 39 GERMANY COMPANION DIAGNOSTICS MARKET BY TECHNOLOGY, 2015 - 2018, USD MILLION
TABLE 40 GERMANY COMPANION DIAGNOSTICS MARKET BY TECHNOLOGY, 2019 - 2025, USD MILLION
TABLE 41 GERMANY COMPANION DIAGNOSTICS MARKET BY INDICATION, 2015 - 2018, USD MILLION
TABLE 42 GERMANY COMPANION DIAGNOSTICS MARKET BY INDICATION, 2019 - 2025, USD MILLION
TABLE 43 GERMANY COMPANION DIAGNOSTICS MARKET BY CANCER TYPE, 2015 - 2018, USD MILLION
TABLE 44 GERMANY COMPANION DIAGNOSTICS MARKET BY CANCER TYPE, 2019 - 2025, USD MILLION
TABLE 45 UK COMPANION DIAGNOSTICS MARKET, 2015 - 2018, USD MILLION
TABLE 46 UK COMPANION DIAGNOSTICS MARKET, 2019 - 2025, USD MILLION
TABLE 47 UK COMPANION DIAGNOSTICS MARKET BY TECHNOLOGY, 2015 - 2018, USD MILLION
TABLE 48 UK COMPANION DIAGNOSTICS MARKET BY TECHNOLOGY, 2019 - 2025, USD MILLION
TABLE 49 UK COMPANION DIAGNOSTICS MARKET BY INDICATION, 2015 - 2018, USD MILLION
TABLE 50 UK COMPANION DIAGNOSTICS MARKET BY INDICATION, 2019 - 2025, USD MILLION
TABLE 51 UK COMPANION DIAGNOSTICS MARKET BY CANCER TYPE, 2015 - 2018, USD MILLION
TABLE 52 UK COMPANION DIAGNOSTICS MARKET BY CANCER TYPE, 2019 - 2025, USD MILLION
TABLE 53 FRANCE COMPANION DIAGNOSTICS MARKET, 2015 - 2018, USD MILLION
TABLE 54 FRANCE COMPANION DIAGNOSTICS MARKET, 2019 - 2025, USD MILLION
TABLE 55 FRANCE COMPANION DIAGNOSTICS MARKET BY TECHNOLOGY, 2015 - 2018, USD MILLION
TABLE 56 FRANCE COMPANION DIAGNOSTICS MARKET BY TECHNOLOGY, 2019 - 2025, USD MILLION
TABLE 57 FRANCE COMPANION DIAGNOSTICS MARKET BY INDICATION, 2015 - 2018, USD MILLION
TABLE 58 FRANCE COMPANION DIAGNOSTICS MARKET BY INDICATION, 2019 - 2025, USD MILLION
TABLE 59 FRANCE COMPANION DIAGNOSTICS MARKET BY CANCER TYPE, 2015 - 2018, USD MILLION
TABLE 60 FRANCE COMPANION DIAGNOSTICS MARKET BY CANCER TYPE, 2019 - 2025, USD MILLION
TABLE 61 RUSSIA COMPANION DIAGNOSTICS MARKET, 2015 - 2018, USD MILLION
TABLE 62 RUSSIA COMPANION DIAGNOSTICS MARKET, 2019 - 2025, USD MILLION
TABLE 63 RUSSIA COMPANION DIAGNOSTICS MARKET BY TECHNOLOGY, 2015 - 2018, USD MILLION
TABLE 64 RUSSIA COMPANION DIAGNOSTICS MARKET BY TECHNOLOGY, 2019 - 2025, USD MILLION
TABLE 65 RUSSIA COMPANION DIAGNOSTICS MARKET BY INDICATION, 2015 - 2018, USD MILLION
TABLE 66 RUSSIA COMPANION DIAGNOSTICS MARKET BY INDICATION, 2019 - 2025, USD MILLION
TABLE 67 RUSSIA COMPANION DIAGNOSTICS MARKET BY CANCER TYPE, 2015 - 2018, USD MILLION
TABLE 68 RUSSIA COMPANION DIAGNOSTICS MARKET BY CANCER TYPE, 2019 - 2025, USD MILLION
TABLE 69 SPAIN COMPANION DIAGNOSTICS MARKET, 2015 - 2018, USD MILLION
TABLE 70 SPAIN COMPANION DIAGNOSTICS MARKET, 2019 - 2025, USD MILLION
TABLE 71 SPAIN COMPANION DIAGNOSTICS MARKET BY TECHNOLOGY, 2015 - 2018, USD MILLION
TABLE 72 SPAIN COMPANION DIAGNOSTICS MARKET BY TECHNOLOGY, 2019 - 2025, USD MILLION
TABLE 73 SPAIN COMPANION DIAGNOSTICS MARKET BY INDICATION, 2015 - 2018, USD MILLION
TABLE 74 SPAIN COMPANION DIAGNOSTICS MARKET BY INDICATION, 2019 - 2025, USD MILLION
TABLE 75 SPAIN COMPANION DIAGNOSTICS MARKET BY CANCER TYPE, 2015 - 2018, USD MILLION
TABLE 76 SPAIN COMPANION DIAGNOSTICS MARKET BY CANCER TYPE, 2019 - 2025, USD MILLION
TABLE 77 ITALY COMPANION DIAGNOSTICS MARKET, 2015 - 2018, USD MILLION
TABLE 78 ITALY COMPANION DIAGNOSTICS MARKET, 2019 - 2025, USD MILLION
TABLE 79 ITALY COMPANION DIAGNOSTICS MARKET BY TECHNOLOGY, 2015 - 2018, USD MILLION
TABLE 80 ITALY COMPANION DIAGNOSTICS MARKET BY TECHNOLOGY, 2019 - 2025, USD MILLION
TABLE 81 ITALY COMPANION DIAGNOSTICS MARKET BY INDICATION, 2015 - 2018, USD MILLION
TABLE 82 ITALY COMPANION DIAGNOSTICS MARKET BY INDICATION, 2019 - 2025, USD MILLION
TABLE 83 ITALY COMPANION DIAGNOSTICS MARKET BY CANCER TYPE, 2015 - 2018, USD MILLION
TABLE 84 ITALY COMPANION DIAGNOSTICS MARKET BY CANCER TYPE, 2019 - 2025, USD MILLION
TABLE 85 REST OF EUROPE COMPANION DIAGNOSTICS MARKET, 2015 - 2018, USD MILLION
TABLE 86 REST OF EUROPE COMPANION DIAGNOSTICS MARKET, 2019 - 2025, USD MILLION
TABLE 87 REST OF EUROPE COMPANION DIAGNOSTICS MARKET BY TECHNOLOGY, 2015 - 2018, USD MILLION
TABLE 88 REST OF EUROPE COMPANION DIAGNOSTICS MARKET BY TECHNOLOGY, 2019 - 2025, USD MILLION
TABLE 89 REST OF EUROPE COMPANION DIAGNOSTICS MARKET BY INDICATION, 2015 - 2018, USD MILLION
TABLE 90 REST OF EUROPE COMPANION DIAGNOSTICS MARKET BY INDICATION, 2019 - 2025, USD MILLION
TABLE 91 REST OF EUROPE COMPANION DIAGNOSTICS MARKET BY CANCER TYPE, 2015 - 2018, USD MILLION
TABLE 92 REST OF EUROPE COMPANION DIAGNOSTICS MARKET BY CANCER TYPE, 2019 - 2025, USD MILLION
TABLE 93 KEY INFORMATION – AGILENT TECHNOLOGIES, INC.
TABLE 94 KEY INFORMATION – ALMAC GROUP
TABLE 95 KEY INFORMATION – ARUP LABORATORIES, INC.
TABLE 96 KEY INFORMATION – ABBOTT LABORATORIES
TABLE 97 KEY INFORMATION – DANAHER CORPORATION
TABLE 98 KEY INFORMATION – THERMO FISHER SCIENTIFIC, INC.
TABLE 99 KEY INFORMATION – HOLOGIC, INC.
TABLE 100 KEY INFORMATION – NOVARTIS AG
TABLE 101 KEY INFORMATION – ILLUMINA, INC.
TABLE 102 KEY INFORMATION – QIAGEN N.V.
TABLE 1 EUROPE COMPANION DIAGNOSTICS MARKET, 2015 - 2018, USD MILLION
TABLE 2 EUROPE COMPANION DIAGNOSTICS MARKET, 2019 - 2025, USD MILLION
TABLE 3 EUROPE COMPANION DIAGNOSTICS MARKET BY TECHNOLOGY, 2015 - 2018, USD MILLION
TABLE 4 EUROPE COMPANION DIAGNOSTICS MARKET BY TECHNOLOGY, 2019 - 2025, USD MILLION
TABLE 5 EUROPE IMMUNOHISTOCHEMISTRY MARKET BY COUNTRY, 2015 - 2018, USD MILLION
TABLE 6 EUROPE IMMUNOHISTOCHEMISTRY MARKET BY COUNTRY, 2019 - 2025, USD MILLION
TABLE 7 EUROPE POLYMERASE CHAIN REACTION (PCR) MARKET BY COUNTRY, 2015 - 2018, USD MILLION
TABLE 8 EUROPE POLYMERASE CHAIN REACTION (PCR) MARKET BY COUNTRY, 2019 - 2025, USD MILLION
TABLE 9 EUROPE NEXT GENERATION SEQUENCING (NGS) MARKET BY COUNTRY, 2015 - 2018, USD MILLION
TABLE 10 EUROPE NEXT GENERATION SEQUENCING (NGS) MARKET BY COUNTRY, 2019 - 2025, USD MILLION
TABLE 11 EUROPE IN SITU HYBRIDIZATION MARKET BY COUNTRY, 2015 - 2018, USD MILLION
TABLE 12 EUROPE IN SITU HYBRIDIZATION MARKET BY COUNTRY, 2019 - 2025, USD MILLION
TABLE 13 EUROPE OTHER TECHNOLOGY MARKET BY COUNTRY, 2015 - 2018, USD MILLION
TABLE 14 EUROPE OTHER TECHNOLOGY MARKET BY COUNTRY, 2019 - 2025, USD MILLION
TABLE 15 EUROPE COMPANION DIAGNOSTICS MARKET BY INDICATION, 2015 - 2018, USD MILLION
TABLE 16 EUROPE COMPANION DIAGNOSTICS MARKET BY INDICATION, 2019 - 2025, USD MILLION
TABLE 17 EUROPE ONCOLOGY COMPANION DIAGNOSTICS MARKET BY COUNTRY, 2015 - 2018, USD MILLION
TABLE 18 EUROPE ONCOLOGY COMPANION DIAGNOSTICS MARKET BY COUNTRY, 2019 - 2025, USD MILLION
TABLE 19 EUROPE COMPANION DIAGNOSTICS MARKET BY CANCER TYPE, 2015 - 2018, USD MILLION
TABLE 20 EUROPE COMPANION DIAGNOSTICS MARKET BY CANCER TYPE, 2019 - 2025, USD MILLION
TABLE 21 EUROPE BREAST CANCER COMPANION DIAGNOSTICS BY COUNTRY, 2015 - 2018, USD MILLION
TABLE 22 EUROPE BREAST CANCER COMPANION DIAGNOSTICS BY COUNTRY, 2019 - 2025, USD MILLION
TABLE 23 EUROPE COLORECTAL CANCER COMPANION DIAGNOSTICS BY COUNTRY, 2015 - 2018, USD MILLION
TABLE 24 EUROPE COLORECTAL CANCER COMPANION DIAGNOSTICS BY COUNTRY, 2019 - 2025, USD MILLION
TABLE 25 EUROPE LUNG CANCER COMPANION DIAGNOSTICS BY COUNTRY, 2015 - 2018, USD MILLION
TABLE 26 EUROPE LUNG CANCER COMPANION DIAGNOSTICS BY COUNTRY, 2019 - 2025, USD MILLION
TABLE 27 EUROPE BLOOD CANCER COMPANION DIAGNOSTICS BY COUNTRY, 2015 - 2018, USD MILLION
TABLE 28 EUROPE BLOOD CANCER COMPANION DIAGNOSTICS BY COUNTRY, 2019 - 2025, USD MILLION
TABLE 29 EUROPE OTHER CANCER TYPE COMPANION DIAGNOSTICS MARKET BY COUNTRY, 2015 - 2018, USD MILLION
TABLE 30 EUROPE OTHER CANCER TYPE COMPANION DIAGNOSTICS MARKET BY COUNTRY, 2019 - 2025, USD MILLION
TABLE 31 EUROPE NEUROLOGY COMPANION DIAGNOSTICS MARKET BY COUNTRY, 2015 - 2018, USD MILLION
TABLE 32 EUROPE NEUROLOGY COMPANION DIAGNOSTICS MARKET BY COUNTRY, 2019 - 2025, USD MILLION
TABLE 33 EUROPE OTHER INDICATIONS COMPANION DIAGNOSTICS MARKET BY COUNTRY, 2015 - 2018, USD MILLION
TABLE 34 EUROPE OTHER INDICATIONS COMPANION DIAGNOSTICS MARKET BY COUNTRY, 2019 - 2025, USD MILLION
TABLE 35 EUROPE COMPANION DIAGNOSTICS MARKET BY COUNTRY, 2015 - 2018, USD MILLION
TABLE 36 EUROPE COMPANION DIAGNOSTICS MARKET BY COUNTRY, 2019 - 2025, USD MILLION
TABLE 37 GERMANY COMPANION DIAGNOSTICS MARKET, 2015 - 2018, USD MILLION
TABLE 38 GERMANY COMPANION DIAGNOSTICS MARKET, 2019 - 2025, USD MILLION
TABLE 39 GERMANY COMPANION DIAGNOSTICS MARKET BY TECHNOLOGY, 2015 - 2018, USD MILLION
TABLE 40 GERMANY COMPANION DIAGNOSTICS MARKET BY TECHNOLOGY, 2019 - 2025, USD MILLION
TABLE 41 GERMANY COMPANION DIAGNOSTICS MARKET BY INDICATION, 2015 - 2018, USD MILLION
TABLE 42 GERMANY COMPANION DIAGNOSTICS MARKET BY INDICATION, 2019 - 2025, USD MILLION
TABLE 43 GERMANY COMPANION DIAGNOSTICS MARKET BY CANCER TYPE, 2015 - 2018, USD MILLION
TABLE 44 GERMANY COMPANION DIAGNOSTICS MARKET BY CANCER TYPE, 2019 - 2025, USD MILLION
TABLE 45 UK COMPANION DIAGNOSTICS MARKET, 2015 - 2018, USD MILLION
TABLE 46 UK COMPANION DIAGNOSTICS MARKET, 2019 - 2025, USD MILLION
TABLE 47 UK COMPANION DIAGNOSTICS MARKET BY TECHNOLOGY, 2015 - 2018, USD MILLION
TABLE 48 UK COMPANION DIAGNOSTICS MARKET BY TECHNOLOGY, 2019 - 2025, USD MILLION
TABLE 49 UK COMPANION DIAGNOSTICS MARKET BY INDICATION, 2015 - 2018, USD MILLION
TABLE 50 UK COMPANION DIAGNOSTICS MARKET BY INDICATION, 2019 - 2025, USD MILLION
TABLE 51 UK COMPANION DIAGNOSTICS MARKET BY CANCER TYPE, 2015 - 2018, USD MILLION
TABLE 52 UK COMPANION DIAGNOSTICS MARKET BY CANCER TYPE, 2019 - 2025, USD MILLION
TABLE 53 FRANCE COMPANION DIAGNOSTICS MARKET, 2015 - 2018, USD MILLION
TABLE 54 FRANCE COMPANION DIAGNOSTICS MARKET, 2019 - 2025, USD MILLION
TABLE 55 FRANCE COMPANION DIAGNOSTICS MARKET BY TECHNOLOGY, 2015 - 2018, USD MILLION
TABLE 56 FRANCE COMPANION DIAGNOSTICS MARKET BY TECHNOLOGY, 2019 - 2025, USD MILLION
TABLE 57 FRANCE COMPANION DIAGNOSTICS MARKET BY INDICATION, 2015 - 2018, USD MILLION
TABLE 58 FRANCE COMPANION DIAGNOSTICS MARKET BY INDICATION, 2019 - 2025, USD MILLION
TABLE 59 FRANCE COMPANION DIAGNOSTICS MARKET BY CANCER TYPE, 2015 - 2018, USD MILLION
TABLE 60 FRANCE COMPANION DIAGNOSTICS MARKET BY CANCER TYPE, 2019 - 2025, USD MILLION
TABLE 61 RUSSIA COMPANION DIAGNOSTICS MARKET, 2015 - 2018, USD MILLION
TABLE 62 RUSSIA COMPANION DIAGNOSTICS MARKET, 2019 - 2025, USD MILLION
TABLE 63 RUSSIA COMPANION DIAGNOSTICS MARKET BY TECHNOLOGY, 2015 - 2018, USD MILLION
TABLE 64 RUSSIA COMPANION DIAGNOSTICS MARKET BY TECHNOLOGY, 2019 - 2025, USD MILLION
TABLE 65 RUSSIA COMPANION DIAGNOSTICS MARKET BY INDICATION, 2015 - 2018, USD MILLION
TABLE 66 RUSSIA COMPANION DIAGNOSTICS MARKET BY INDICATION, 2019 - 2025, USD MILLION
TABLE 67 RUSSIA COMPANION DIAGNOSTICS MARKET BY CANCER TYPE, 2015 - 2018, USD MILLION
TABLE 68 RUSSIA COMPANION DIAGNOSTICS MARKET BY CANCER TYPE, 2019 - 2025, USD MILLION
TABLE 69 SPAIN COMPANION DIAGNOSTICS MARKET, 2015 - 2018, USD MILLION
TABLE 70 SPAIN COMPANION DIAGNOSTICS MARKET, 2019 - 2025, USD MILLION
TABLE 71 SPAIN COMPANION DIAGNOSTICS MARKET BY TECHNOLOGY, 2015 - 2018, USD MILLION
TABLE 72 SPAIN COMPANION DIAGNOSTICS MARKET BY TECHNOLOGY, 2019 - 2025, USD MILLION
TABLE 73 SPAIN COMPANION DIAGNOSTICS MARKET BY INDICATION, 2015 - 2018, USD MILLION
TABLE 74 SPAIN COMPANION DIAGNOSTICS MARKET BY INDICATION, 2019 - 2025, USD MILLION
TABLE 75 SPAIN COMPANION DIAGNOSTICS MARKET BY CANCER TYPE, 2015 - 2018, USD MILLION
TABLE 76 SPAIN COMPANION DIAGNOSTICS MARKET BY CANCER TYPE, 2019 - 2025, USD MILLION
TABLE 77 ITALY COMPANION DIAGNOSTICS MARKET, 2015 - 2018, USD MILLION
TABLE 78 ITALY COMPANION DIAGNOSTICS MARKET, 2019 - 2025, USD MILLION
TABLE 79 ITALY COMPANION DIAGNOSTICS MARKET BY TECHNOLOGY, 2015 - 2018, USD MILLION
TABLE 80 ITALY COMPANION DIAGNOSTICS MARKET BY TECHNOLOGY, 2019 - 2025, USD MILLION
TABLE 81 ITALY COMPANION DIAGNOSTICS MARKET BY INDICATION, 2015 - 2018, USD MILLION
TABLE 82 ITALY COMPANION DIAGNOSTICS MARKET BY INDICATION, 2019 - 2025, USD MILLION
TABLE 83 ITALY COMPANION DIAGNOSTICS MARKET BY CANCER TYPE, 2015 - 2018, USD MILLION
TABLE 84 ITALY COMPANION DIAGNOSTICS MARKET BY CANCER TYPE, 2019 - 2025, USD MILLION
TABLE 85 REST OF EUROPE COMPANION DIAGNOSTICS MARKET, 2015 - 2018, USD MILLION
TABLE 86 REST OF EUROPE COMPANION DIAGNOSTICS MARKET, 2019 - 2025, USD MILLION
TABLE 87 REST OF EUROPE COMPANION DIAGNOSTICS MARKET BY TECHNOLOGY, 2015 - 2018, USD MILLION
TABLE 88 REST OF EUROPE COMPANION DIAGNOSTICS MARKET BY TECHNOLOGY, 2019 - 2025, USD MILLION
TABLE 89 REST OF EUROPE COMPANION DIAGNOSTICS MARKET BY INDICATION, 2015 - 2018, USD MILLION
TABLE 90 REST OF EUROPE COMPANION DIAGNOSTICS MARKET BY INDICATION, 2019 - 2025, USD MILLION
TABLE 91 REST OF EUROPE COMPANION DIAGNOSTICS MARKET BY CANCER TYPE, 2015 - 2018, USD MILLION
TABLE 92 REST OF EUROPE COMPANION DIAGNOSTICS MARKET BY CANCER TYPE, 2019 - 2025, USD MILLION
TABLE 93 KEY INFORMATION – AGILENT TECHNOLOGIES, INC.
TABLE 94 KEY INFORMATION – ALMAC GROUP
TABLE 95 KEY INFORMATION – ARUP LABORATORIES, INC.
TABLE 96 KEY INFORMATION – ABBOTT LABORATORIES
TABLE 97 KEY INFORMATION – DANAHER CORPORATION
TABLE 98 KEY INFORMATION – THERMO FISHER SCIENTIFIC, INC.
TABLE 99 KEY INFORMATION – HOLOGIC, INC.
TABLE 100 KEY INFORMATION – NOVARTIS AG
TABLE 101 KEY INFORMATION – ILLUMINA, INC.
TABLE 102 KEY INFORMATION – QIAGEN N.V.
LIST OF FIGURES
FIG 1 METHODOLOGY FOR THE RESEARCH
FIG 1 METHODOLOGY FOR THE RESEARCH
